Kornimate/medical-research-clean huggingface dataset:
population-based registry study on primary hip fracture surgery

Conditions: Hip Fracture

Summary: this study aims to describe primary hip fracture surgeries and to identify patient-related and perioperative risk factors affecting outcomes. it will utilize data from the swedish perioperative registry (spor) and the swedish national patient register to track epidemiological changes, treatment outcomes, and perioperative factors.

hip fractures, a significant health concern among the elderly, necessitate hospitalization and surgical intervention, with high mortality and morbidity rates within the first year post-surgery. the study will retrospectively analyze records of approximately 90,000 patients over 18 who underwent hip fracture surgery between 2018 and 2022. key factors such as age, sex, preoperative health status, and perioperative care methods will be evaluated to determine their impact on complications, reoperation rates, and survival. this research could inform future clinical practices and policies, aiming to optimize the treatment and management of elderly patients with hip fractures.

Eligibility criteria:
inclusion criteria: - patients aged 18+ with hip fractures, identified through icd code s72\*, who underwent surgery during the study period. exclusion criteria: * patients without a swedish personal identification number, as this is necessary to link data across registers.

Keywords: hip fracture primary hip fracture surgery perioperative risk factors reoperation rates mortality geriatric fractures epidemiology swedish perioperative registry (spor) population-based study
lingzhi and sen miao san for the treatment of rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: to study the efficacy of tcm as an effective supplement in addition to the traditional treatment in ra.

it is a prospective, double-blind, randomized, placebo-controlled study in patients with ra. it consists of a 24 - weeks period of randomized double-blind treatment of either tcm(lingzhi and sen miao san)or placebo. primary outcome is assessed by showing a clinical response of at least 20% and 50% as defined by the american college of rheumatology (acr) criteria.secondary outcome is defined as the changes in the number of swollen and tender joint counts, and the levels of esr, crp, the inflammatory markers, cytokine levels and oxidative stress.

Eligibility criteria:
inclusion criteria: * fulfilled the 1987 american college of rheumatology (acr) criteria for ra. * the presence of 2 or more swollen or tender joints, based on 28-joint count. * morning stiffness lasting for 30 minutes. * erythrocyte sedimentation rate (esr) of 28 mm/hour, despite treatment with disease modifying agent including mtx, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study. * patients taking glucocorticoids (prednisone \< 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial. * patients had radiographic erosive diseases. exclusion criteria: * patients who are pregnant or nursing mothers. * severe liver disease (e.g cirrhosis, chronic active hepatitis) * renal impairment (serum creatinine level \> 150mmol/l) * known hypersensitivity to herbal medicine

Keywords: lingzhi sen miao san rheumatoid arthritis
adrenomedullin effect on migraine without patients

Conditions: Headache, Migraine

Summary: am is a naturally occurring peptide in the body and consists of 52 amino acids. am belongs to the calcitonin gene-related peptide (cgrp) superfamily and has several structural, physiological and pharmacological similarities to cgrp, intermdine and amylin. in a randomized double-blind, placebo controlled cross-over design 20 migraine patients without aura recruited to receive infusion of adrenomedullin or placebo (saline).

am is a naturally occurring peptide in the body and consists of 52 amino acids. am belongs to the calcitonin gene-related peptide (cgrp) superfamily and has several structural, physiological and pharmacological similarities to cgrp, intermdine and amylin. in a randomized double-blind, placebo controlled cross-over design 20 migraine patients without aura recruited to receive infusion of adrenomedullin or placebo (saline). a pilot study on healthy volunteers were conducted to determine tolerable dose of adrenomedullin to the main study.

Eligibility criteria:
inclusion criteria: * 18-60 years old * 50-100 kg * migraine without aura according international headache classification disorders 3rd edition exclusion criteria: * tension-type headaches more than 5 days a month on average over the past year. * all other primary headache forms.- * headache later than 48 hours before the start of the trial. * daily intake of medicines of all kinds except oral contraception. * taking any medicine later than 4 times the plasma half-life of that drug (on the day of the trial), except oral contraception. * pregnant or breastfeeding women. * headache on the day of the trial or later than 48 hours before the administration of the trial drug / placebo * migraines within 3 days before the trial date. * anamnestic information or clinical signs (on the day of inclusion): * hypertension (systolic blood pressure\> 150 mmhg and / or diastolic blood pressure\> 100 mmhg) * hypotension (systolic blood pressure \<90 mm hg and / or diastolic blood pressure \<50 mmhg) * cardiovascular diseases of all kinds, including cerebrovascular diseases. * anamnestic or clinical signs of mental illness or abuse. * patients with glaucoma or prostate hyperplasia * anamnestic or clinical signs of illness of any kind that the investigating physician considers relevant for participation in the trial.
study to evaluate the efficacy and safety of cm310 in subjects with igg4-related disease

Conditions: IgG4 Related Disease

Summary: this study is a single-arm study initiated to evaluate the efficacy and safety of cm310 in subjects with recurrent igg4-related disease.

this study includes three stages: screening period, treatment period and safety follow-up period.

Eligibility criteria:
inclusion criteria: * ≥18 years, male and female. * with igg4-related disease. exclusion criteria: * inoculate live vaccine within 4 weeks before screening. * treponema pallidum antibody positive in screening period. * active hepatitis in screening period. * with a history of solid organ or cell transplantation within 6 months before screening. * with other medical or non-medical conditions that are not suitable for the study by the investigator.
relation of implantation site to placental site

Conditions: Placenta Implantation Site

Summary: trans vaginal ultrasound with a partially full bladder will be done at gestational age earlier than 10 weeks to assess the site of intrauterine gestational sac to the endometrial cavity and the distance between the implantation site and the internal cervical os . doppler assessment of the retrochorionic blood flow at the area behind the maximum chorionic tissue to detect resistance index.


Eligibility criteria:
inclusion criteria: * single intrauterine pregnancy * gestational age less than 10 weeks exclusion criteria: * any condition distorting uterine cavity as myoma, uterine anomalies. * absent fetal pulsations * any condition needing termination of early pregnancy as molar pregnancy or severe deteriorating maternal disease

Keywords: implantation site placental site doppler
combination chemotherapy with or without prednisone in treating patients with recurrent and/or metastatic kidney cancer

Conditions: Kidney Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. prednisone may help to relieve symptoms in patients with recurrent and/or metastatic kidney cancer. purpose: phase ii trial to study the effectiveness of combination chemotherapy consisting of vinorelbine and estramustine with or without prednisone in treating patients who have recurrent and/or metastatic kidney cancer.

objectives: i. estimate the response rate of vinorelbine and estramustine in patients with metastatic and/or recurrent renal cell carcinoma. ii. obtain pilot data exploring the value of anti-inflammatory treatment in the management of severe systemic symptoms and improvement of treatment tolerance in this patient population. outline: patients are stratified according to number of risk factors (0,1 versus 2 versus 3). patients receive vinorelbine iv on days 1, 8, 15, 22, 28, and 35. patients also receive estramustine orally twice per day on days 1-7 and an increased dose on days 8-42. a tapered dose of oral prednisone is given to patients with an elevated erythrocyte sedimentation rate. a course of treatment consists of 6 weeks of treatment followed by 2 weeks of rest. patients with stable disease may receive up to 4 courses of treatment. patients who achieve a partial response may undergo surgical resection followed by up to 2 additional courses of treatment or an interleukin-2 treatment regimen. patients with a complete response receive 1 additional course of treatment. patients are followed until death. projected accrual: a maximum of 35 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven metastatic and/or recurrent renal cell carcinoma bidimensionally measurable disease required (outside any prior radiation fields) no untreated brain metastases patient characteristics: age: not specified performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: not pregnant or nursing fertile patients must use effective contraception no other serious illness no serious active infection requiring therapy hiv negative prior concurrent therapy: biologic therapy: no concurrent biologic therapy chemotherapy: no prior vinca alkaloid no other concurrent chemotherapy endocrine therapy: no concurrent hormone therapy no concurrent corticosteroids (topical or inhaled corticosteroids allowed) radiotherapy: at least 4 weeks since prior radiotherapy less than 25% of bone marrow irradiated no concurrent radiotherapy surgery: at least 3 weeks since prior surgery other: no other concurrent investigational drugs

Keywords: stage iv renal cell cancer recurrent renal cell cancer
intra arterial (ia) steroids infusion for hepatic acute hepatic graft versus host disease (agvhd)

Conditions: Acute Graft Versus Host Disease

Summary: post allogeneic hematopoietic stem cell transplantation (hsct) patients with steroid resistant acute gvhd localised to the liver will receive 24 hours continuous intra-arterial infusion of methylprednisolone.

the study population will include 30 patients with sr agvhd having an index of b, c, or d on the ibmtr severity index localized to the liver. standard treatment for sr agvhd includes: iv cyclosporine or tacrolimus with adjusted doses depending on serum levels and methylprednisolone or prednisone 2 mg/kg/d. this treatment may be continued during the study period although steroid taper down should be attempted if clinically possible. gvhd diagnosis will be based upon clinical criteria and biopsy (if needed) from an involved organ. gvhd will be graded according to the international bone marrow transplantation registry (ibmtr) severity index. intra-arterial treatment should be given in less than 72h from completion of inclusion criteria. partially responding or non-responding patients may receive a second treatment within 14 days of the initial intra-arterial treatment, at the discretion of the treating physician. definitions hepatic response: * initial response - the day in which bilirubin level began to decrease. * partial response 75 - the day in which bilirubin level decreased below 75% of basal level. * partial response 50 - the day in which bilirubin level decreased below 50% of basal level. * partial response 25 - the day in which bilirubin level decreased below 25% of basal level. * complete response - the day in which bilirubin level decreased to normal level.

Eligibility criteria:
inclusion criteria: * recipient of allogeneic stem cell transplantation. * age\>18 years. * post stem cells transplant \<100 days. * agvhd of liver, ibmtr index b, c, d. * resistant agvhd - patients will be eligible for inclusion if they developed grade b-d agvhd with progression after 3 days standard treatment or unresponsive to at least 7 days standard treatment or incomplete response to standard treatment after 14 days. * has received no 1st line treatment for steroid refractory agvhd. * signed a written informed consent exclusion criteria: * not fulfilling any of the inclusion criteria. * active life-threatening infection. * inability to comply with study requirements. * inability to give informed consent. * contraindication to arterial catheterization (uncorrectable coagulopathy, severe allergic reaction to contrast material or others). * inability to give the first intra-arterial treatment in less than 72h from completion of inclusion criteria * an ibmtr index ≤ a. * refractory skin agvhd or severe diarrhea.. * pregnant or breast-feeding female or childbearing potential. * known to be hiv positive. * has been diagnosed with veno-occlusive disease. * has been diagnosed with multi organ failure. * known renal failure egfr \<30

Keywords: acute graft versus host disease intra arterial steroid infusion steroid resistant acute hepatic graft versus host disease
diet in the management of acromegaly

Conditions: Acromegaly

Summary: impact of low carbohydrate and low gluten diet on acromegaly progression, symptoms, complications, and treatment outcomes.


Eligibility criteria:
inclusion criteria: * diagnosis of acromegaly. exclusion criteria: * diet restrictions.
efficacy and safety of ingenol mebutate gel 0.06% when applied once daily for 2, 3 or 4 consecutive days to a treatment area of approximately 250 cm2 on trunk and extremities in subjects with actinic keratosis

Conditions: Actinic Keratosis

Summary: this is a randomised, double-blind, parallel groups, vehicle controlled, 8-week phase 2 trial. the objective is to evaluate efficacy of ingenol mebutate gel 0.06 % after once daily treatment for 2, 3 or 4 consecutive days compared to vehicle gel


Eligibility criteria:
inclusion criteria: subjects with 5 to 20 clinically typical, visible and discrete aks within a contiguous area of approximately 250 cm² sun-damaged skin on either trunk (except chest), or extremities exclusion criteria: * location of the treatment area (trunk (except chest) or extremities) * within 5 cm of an incompletely healed wound, * within 5 cm of a suspected basal cell carcinoma (bcc) or squamous cell carcinoma (scc) * prior treatment with ingenol mebutate within the selected treatment area * lesions in the treatment area that have: * atypical clinical appearance (e.g., hypertrophic,hyperkeratotic or cutaneous horns) and/or, * recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions)
the effectiveness and cost-effectiveness of motion style acupuncture treatment (msat) for acute neck pain: a multi-center randomized controlled trial

Conditions: Acute Neck Pain

Summary: the investigators will evaluate the comparative effectiveness and safety of motion style acupuncture treatment (msat) therapy for acute neck pain compared to acupuncture.

this is a multi-center, randomized, controlled, comparative effectiveness clinical trial for acute neck pain. motion style acupuncture requires a part of the patient's body to move passively or actively while acupuncture needles are retained.

Eligibility criteria:
inclusion criteria: * neck pain onset or worsen within one month * vas of neck pain on movement or at rest of 5 or higher * age between 19 and 70 years old * participants who wrote a informed consent exclusion criteria: * participants who diagnosed with the serious disease that can cause pain (e.g. migration of cancer reaching to spine, fracture of spine, dislocation of spine) * progressive neurologic deficits or severe neurologic deficits * participants who diagnosed with a soft tissue disease that can cause pain (cancer, fibromyalgia, ra, or goat) * chronic disease (e.g. cardiovascular disease, kidney disease, dementia, diabetic neuropathy, or epilepsy) * participants taking steroids, immunosuppressants, or psychotropic medication * participants who could be inadequate or unsafe at acupuncture (e.g. hemorrhagic disease, severe diabetes or taking anticoagulant drug) * participants who took nsaids or acupuncture within 3 days * participants who had undergone cervical surgery within 3 months * participants who had a traffic accident within a month * pregnant or women who planned to conceive * participants who had participated in other clinical trial within 1 month, or have plan for participation in other trial within 6 months from enrollment * participants who can not write informed consent * participants who is difficult to participate in the trial according to investigator's decision
impact of reducing colistin use on colistin resistance in humans and poultry in indonesia

Conditions: Colonization, Asymptomatic; Colistin; Mcr-1; Antimicrobial Resistance

Summary: colistin (polymyxin e) is considered a last resort antimicrobial for treatment of infections with multidrug- resistant bacteria, classified by who as 'highest prioritized, critically important for human medicine'. who suggests to ban or highly restrict its use in animals. in indonesia, colistin resistance in human escherichia coli isolates is poorly characterized as it requires specific non-routine tests. presence of colistin resistance in e. coli in poultry resulted in a ban for livestock in indonesia in 2020. however, colistin is still suspected to be routinely used in humans in multiple settings but the reasons for these practices are poorly understood. the ban on colistin use in livestock offers a unique opportunity to assess the impact of this intervention on colistin resistance in humans and animals, and how a one health perspective can strengthen this intervention. this project aims to: i) determine phenotypic and genotypic colistin resistance in e. coli from humans and poultry in indonesia; ii) assess the impact of the colistin ban on resistance in e. coli in animals and humans; iii) estimate the transmission of colistin resistance between animals and humans; iv) study colistin use and perceptions at the community level; and v) expand the initial colistin ban in the animal production sector into an integrative multi-sectorial one health intervention, which will be designed and implemented using a community participatory approach. this project will provide a strong scientific basis to amr policies in indonesia, with great significance across southeast asia.


Eligibility criteria:
inclusion criteria: * all individuals with age \>= 18 years old, that are willing to participate exclusion criteria: * vomiting and/or diarrhea

Keywords: escherichia coli
beneficial effects of lactobacillus reuteri dsm 17938 supplementation on asthmatic children

Conditions: Airways Allergic Inflammation of Asthmatic Children

Summary: objective the aim of the trial is to evaluate the beneficial effects of the oral administration of the probiotic l. reuteri (reuterin®) on the airways allergic inflammation in children with mild to moderate persistent asthma. study design this is a randomized, double-blind, placebo controller trial. 50 children will be enrolled (age range 6-14 years), affected by mild to moderate persistent asthma based on the gina guidelines and allergic to acarus (dermatophagoides farinae and d. pteronyssinus ++/+++). at the enrollment period all children have to show asthmatic symptoms and to be under antileukotrienes treatment (montelukast 5mg/die) based on the gina guidelines. any inhaling corticosteroids therapies have to be stopped 8 weeks before the trial beginning. patients will be randomly divided into 2 treatment groups: group a: 25 patients will take antileukotrienes + l. reuteri drops (108 cfu = 5 drops daily). group b: 25 patients will take antileukotrienes + placebo. at the enrollment period (t0), after the 1st and the 2nd month of supplementation (t1 and t2), and also 1 month after the supplementation end (t3), all patients will be clinically evaluated through spirometry, feno determination and exhale condensate analysis. during the entire trial period the number of asthmatic exacerbations and the use of beta-2 antagonists will be monitored by a diary properly examined at t1, t2 and t3. all children will be enrolled at the asthma and infant respiratory physiopathology unit "michele miraglia del giudice" of the "f. fede" pediatric department. the analysis of the inflammatory markers on the exhaled condensate will be performer at t1, t2 and t3 in the pharmacology unit of the experimental medicine department. during the trial it will be possible to administer only salbutamole mdi if it needed. if patients will be administered with any systemic corticosteroids they will exit from the trial. at the enrolment period all patients will receive the completed information on the trial and the informed consent will be properly signed.


Eligibility criteria:
inclusion criteria: * children with age range 6-14 years * informed consent signed exclusion criteria: * participation to other clinical trials * informed consent not signed

Keywords: asthmatic children
nitric oxide during cardiopulmonary bypass in neonates to reduce risk of acute kidney injury

Conditions: Acute Kidney Injury; Congenital Heart Disease

Summary: acute kidney injury following cardiac surgery for congenital heart defects in children is a major cause of both short- and long-term morbidity and mortality, affecting up to 60% of high risk patients. despite effort, to date, no successful therapeutic agent has gained widespread success in preventing this postoperative decline in renal function. based on preliminary data available in the literature, we hypothesize that nitric oxide (gno), administered during cardiopulmonary bypass (cpb), may reduce the risk of acute kidney injury (aki) via mechanisms of reduced inflammation and vasodilation. in this pilot study, 40 neonates undergoing cardiac surgery will be randomized to receive intraoperative administration of 20 ppm of nitric oxide to the oxygenator of the cardiopulmonary bypass circuit or standard cpb with no additional gas.


Eligibility criteria:
inclusion criteria: * neonates (≤31 days) undergoing cardiac surgery with cardiopulmonary bypass for congenital heart disease exclusion criteria: * 1. failure to obtain informed consent from parent/guardian, * clinical signs of preoperative persistent elevated pulmonary vascular resistance, * emergency surgery, * episode of cardiac arrest within 1 week before surgery, * recent treatment with steroids and/or a condition that may require treatment with steroids (excluding steroid administration specifically for cpb), * use of inhaled no (ino) immediately prior to surgery, * structural renal abnormalities by ultrasound, * preoperative aki, * use of other investigational drugs, * weight less than \<2.2 kg, * gestational age \<36 weeks, * major extracardiac congenital anomalies.